Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ754MR)

This product GTTS-WQ754MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ754MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9757MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ14451MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ6987MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ3866MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ6890MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ1970MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ14350MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ11119MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-060
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW